Virtue Diagnostic signed the global exclusive distribution rights contract with Revvity
Virtue Diagnostic and Revvity signed an exclusive global distribution rights contract, according to which, starting from January 1, 2024, Revvity will exclusively supply Virtue Diagnostic with instruments, reagents and consumables for time-resolved fluorescence (TRF) immunoassay platform, PCR platform for infectious disease diagnosis (except blood bank business) and POCT platform for heart and inflammation markers (SuperFlex), and license Virtue Diagnostic to market and promote authorized products in the global region.
At the same time to undertake all after-sales services of authorized products, the agreement is an indefinite long-term contract. While fully taking over the marketing, promotion and after-sales service of authorized products, Virtue Diagnostic will continue to invest R&D resources to continue to develop related product lines and begin to localize production and registration in emerging markets at the right time to benefit more people.
Illumina works with Sinocare to promote the localization of chip scanners and expand the local application of medical health genomics
Illumina, the global leader in gene sequencing and chip technology, and Sinocare, the world's leading diabetes digital management expert, officially entered a strategic cooperation. The two sides will take the localization of iScan® high-end chip scanners as a starting point and use the technical advantages and channel resources of both sides to jointly expand the application of genomics in precision health management.
The cooperation aims to faster and better meet the needs of the Chinese local market in the fields of reproductive genetics, chronic disease prevention and treatment, and contribute to the realization of the "Healthy China" strategy and the high-quality development of national health.
MGI Tech and Xiji Biotechnology developed new cell storage products based on automated liquid nitrogen tank system
Xiji Biotechnology signed a strategic cooperation agreement with MGI Tech. According to the agreement, the two parties will cooperate closely based on MGI Tech's automated liquid nitrogen tank system to develop products suitable for applications in the field of cell storage.
Xiji Biotechnology and MGI Tech will mobilize their respective superior resources to jointly promote the standardized application and market promotion of automated liquid nitrogen tank systems in the CDMO industry to achieve win-win cooperation and sustainable development.
Lyher¡¯ s drug detection products obtained FDA (510k) registration certificate
Recently, Lyher received a notice from the United States Food and Drug Administration (FDA), the company's many drug detection series products (K232597) and marijuana detection series products (K232604) obtained the United States FDA 510k certification.
The acquisition of these two certificates marks the official entry of the company's main drug detection series products into the US market, helping the company to explore the US drug home self-test and professional testing market, which is a milestone for the company to further expand the international market.
Chinese AI firm iFlyTek¡¯s healthcare unit plans Hong Kong IPO
Chinese artificial intelligence (AI) company iFlyTek said it plans to spin off its healthcare services subsidiary, iFlyHealth, with a listing in Hong Kong.
Shenzhen-listed iFlyTek said the initial size of an iFlyHealth listing will not be more than 20.0899 million shares, with an overallotment option of up to 15 per cent. The total number of shares is proposed to not exceed 23.1034 million.
The move will allow iFlyHealth to obtain financing through the capital markets in Hong Kong, which will help it to maintain its leading role in the field of medical AI and increase its international influence, iFlyTek said in a statement late on Tuesday.
